160
Participants
Start Date
July 25, 2022
Primary Completion Date
December 20, 2023
Study Completion Date
October 16, 2024
Pembrolizumab
200 mg by IV infusion on Day 1 of each 21-day cycle
Paclitaxel
175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Carboplatin
AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
Avastin
According to local practice and at the choice of the investigator.
MK-4830
800 mg by IV infusion on Day 1 of each 21-day cycle
Docetaxel
75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Taichung Veterans General Hospital-GYNECOLOGY ( Site 1202), Taichung
National Cheng Kung University Hospital ( Site 1201), Tainan City
Antwerp University Hospital-Oncology ( Site 1301), Edegem
UZ Leuven ( Site 1300), Leuven
AZ Maria Middelares-IKG ( Site 1302), Ghent
National Taiwan University Hospital-Internal Medicine ( Site 1200), Taipei
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107), New York
Memorial Sloan Kettering Cancer Center ( Site 0102), New York
Mackay Memorial Hospital ( Site 1204), Taipei
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116), Mineola
Roswell Park Cancer Institute ( Site 0106), Buffalo
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 050, Milan
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 0501), Milan
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid
Mayo Clinic in Florida ( Site 0101), Jacksonville
Miami Cancer Institute at Baptist Health, Inc. ( Site 0110), Miami
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County
Sanford Cancer Center-Gynecologic Oncology ( Site 0115), Sioux Falls
Northwestern Memorial Hospital ( Site 0104), Chicago
Washington University ( Site 0113), St Louis
University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108), Aurora
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 0, Napoli
Fred Hutchinson Cancer Center ( Site 0100), Seattle
National University Hospital ( Site 1502), Singapore
National Cancer Centre Singapore ( Site 1501), Singapore
ONCOCENTRO APYS-ACEREY ( Site 0904), Viña del Mar
Rambam Health Care Campus-Gyneco-oncology unit ( Site 0602), Haifa
James Lind Centro de Investigación del Cáncer ( Site 0903), Temuco
Sheba Medical Center-ONCOLOGY ( Site 0600), Ramat Gan
FALP ( Site 0905), Santiago
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0900), Santiago
Shaare Zedek Medical Center ( Site 0601), Jerusalem
Rutgers Cancer Institute of New Jersey ( Site 0114), New Brunswick
Centre Hospitalier de l'Université de Montréal ( Site 0300), Montreal
McGill University Health Centre ( Site 0301), Montreal
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 0502), Rome
Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 0709), Poznan
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0701), Siedlce
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warsaw
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi, Gdansk
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0708), Kielce
Seoul National University Hospital ( Site 0801), Seoul
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 0800), Seoul
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1103), Hospitalet
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY